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Alpha-1 acid glycoprotein (AGP) is a highly glycosylated, negatively charged plasma protein suggested to have anti-inﬂammatory
and/or immunomodulatory activities. Puriﬁcation of AGP could be simpliﬁed if methods that exploit its high solubility under
chemically harshconditions could be demonstrated to leave the protein in its native conformation.Procedures involvingexposure
of AGP to hot phenol or sulphosalicylicacid (SSA) were compared to solely chromatographic methods. Hot phenol-puriﬁed AGP
was more rapidly cleared from mice in vivo following intravenous injection than chromatographically puriﬁed AGP. In contrast,
SSA-puriﬁed AGP demonstrated an identical in vivo clearance proﬁle and circular dichroism spectrum to chromatographically
puriﬁed AGP. Similarly, no diﬀerences in susceptibility to enzymatic deglycosylation or reactivity with Sambucus nigra lectin were
detected between AGP puriﬁed via the two methods. Incorporation of the SSA step in the puriﬁcation scheme for AGP eliminated
the need for a large (4mL resin/mL of plasma) initial chromatographic step and simpliﬁed its puriﬁcation without causing any
detectable distortion in the conformation of the protein. Conﬁrmation that this procedure is nondenaturing will simplify AGP
puriﬁcation and investigation of its possible biologicalroles in laboratory animals.
1.Introduction
Alpha-1 acid glycoprotein (AGP; also known as oroso-
mucoid) is one of the most heavily glycosylated proteins
in human plasma, with approximately 45% of its 44kDa
molecular weight being contributed by N-linked glycans [1].
TheseglycansclusterontheN-terminalhalfofthe183amino
acid AGP polypeptide chain and are attached to Asn 15, 38,
54, 75, and 85 [2]. AGP exhibits an unusually high degree
of glycan branching, being one of the few plasma proteins
possessing not only di- and tri-antennary, but also tetra-
antennary glycans [3]. This degree of branching indirectly
results in a high sialic acid composition, which contributes
signiﬁcantly to the unusually low isoelectric point (pI) of the
protein, which ranges from 2.8 to 3.8 due to the existence
of multiple isoforms [4]. Recently, a high-resolution crystal
structure of recombinant, nonglycosylated AGP revealed the
AGP polypeptide to be folded into an eight-stranded β-
barrel, characteristic of members of the lipocalin protein
family [5].
The physiological role of AGP is unclear. Indirect
immunomodulatory eﬀects of AGP on diﬀerent classes of
leukocytes have been reported [6–10], in addition to poten-
tial roles in promoting endothelial barrier function [11–13],
and in directly binding both lipopolysaccharide [14]a n d
neutralandbasic drugs[5].Duringtheacutephase response,
circulating levels of human AGP rise form two- to sevenfold
[15].If this increase is part of an anti-inﬂammatory response
by the host, then mimicking it pharmacologically could
provide a therapeutic advantage. In this regard, several
laboratories have reported the ability of exogenous bovine
or human AGP to either dampen inﬂammatory responses or2 Journal of Biomedicine and Biotechnology
decrease mortality in rodent models of hypovolemia, septic
shock, or sepsis, at doses in the 0.2–0.4g intravenous AGP
per kg body weight range [16–20].
Because AGP is neither an enzyme nor an enzyme
inhibitor, optimizing its stepwise puriﬁcation from plasma
is challenging and cannot rely on traditional measurements
of stepwise changes in speciﬁc enzymatic activity. Many
protocols exploit the low pI and/or extremely high solubility
of AGP to achieve its enrichment [21–26]. However, such
procedures rely at least in part on relatively harsh conditions
that could disrupt the natural conformation of the protein
and/or its glycan chains. To extend our preliminary ﬁndings
of anti-inﬂammatory eﬀects of AGP administration in a
mouse model of early sepsis as a possible prelude to
translating the approach to humans, we sought to improve
the ease with which AGP could be puriﬁed from human
plasma. WeavoidedcommercialsourcesofAGPbecauseona
high mg to g scale, their cost is prohibitive for research. Here
we compare several procedures for the puriﬁcation of AGP
fromhumanplasmaandreportthatbriefexposureofAGPto
sulphosalicylic acid facilitated the isolation of puriﬁed AGP
indistinguishable in either a biological or biophysical assay
from that obtained in a longer procedure employing a more
cumbersome chromatographic step.
2.Materialsand Methods
2.1. Materials. Aﬃ-Gel Blue resin (150–300μmp a r t i c l e
size), Bio-Gel HT hydroxyapatite resin, CHT Ceramic
hydroxyapatite resin, and Bio-Beads SM-2 adsorbent were
from Bio-Rad Laboratories (Hercules, CA). HiTrap Blue
prepacked columns (volume 5mL) were purchased from
GE Healthcare (Piscataway, NJ). Sulphosalicylic acid, goat
antihuman AGP antiserum, and puriﬁed human AGP
were from Sigma (St. Louis, MO). Horseradish peroxidase-
(HRP-) conjugated rabbit antihuman AGP IgG was from
Rockland Immunochemicals, Inc. (Gilbertsville, PA). The
PyroGene endotoxin assay was from Lonza (formerly Cam-
brex) BioScience (Walkersville, MD). New Zealand White
rabbitsand C57/Bl6mice were purchased from CharlesRiver
Laboratories (St. Constant, QC).
2.2. Plasma. Human plasma was prepared from whole blood
collected into 1/7 volume of citrate-phosphate-dextrose
anticoagulant. Blood donors were healthy laboratory staﬀ
volunteerswhose blood was obtained with informed consent
under the terms of a protocol approved by the Research
Ethics Board of Hamilton Health Sciences Corporation.
Plasma from 23 donors was pooled and aliquoted prior
to freezing at −80◦C. All AGP preparations in this study
therefore were derived from the same source material.
2.3. AGP ELISA. AGP was quantiﬁed in solutions ranging
in complexity from plasma to puriﬁed AGP, using a sand-
wich enzyme-linked immunosorbent assay (ELISA). Goat
antihuman AGP antiserum diluted to 2.5μg/mL in 0.05M
sodium carbonate pH 9.6 was immobilized onto microtiter
plate wells overnight at 4◦C. Wells were then blocked with
1% (w/vol) BSA in phosphate-buﬀered saline (PBS), washed
with PBS supplemented with 0.1% (vol/vol) Tween 20
(PBS-T), and incubated either with samples or commercial
puriﬁed AGP standards, both diluted in 1% (w/vol) nonfat
skim milk powder in PBS-T (MPBS-T). Following PBS-
T washes, plates were exposed to HRP-conjugated rabbit
antihuman AGP IgG diluted 1:5000 in MPBS-T and were
developed using o-phenylenediamine dihydrochloride as a
chromogenic substrate. Colour developmentwas stopped by
addition of 1/3 volume of 2.5M H2SO4 and quantiﬁed as
the absorbance at 490nm, using a BIO-TEK EL808 plate
reader (Winooski, VT). All antibody reactions took place at
room temperature for 90minutes. The OD490 correlated best
(r2 > 0.95) with AGP dilutions between 10 and 100ng/mL.
2.4. Protein Analysis. Total protein concentration was deter-
mined by the method of Bradford [27], using either BSA
or AGP as a standard. Polypeptide composition of pro-
teinaceous solutions was examined electrophoretically using
SDS polyacrylamide gel electrophoresis (SDS-PAGE) using
the Mini-Protean II electrophoresis system as directed by
its manufacturer (Bio-Rad). Immunoblotting was carried
out as described [28]u s i n gt h es a m eH R P - c o n j u g a t e da n t i -
AGP IgG as in the ELISA. Sambucus nigra agglutinin (SNA)
reactive proteins were detected on nitrocellulose using a DIG
Glycan Diﬀerentiation Kit (Roche Diagnostics, Mannheim,
Germany). Insomeexperiments, terminalsialicacidresidues
were removed from AGP glycans using neuraminidase; in
others the puriﬁed protein was enzymatically deglycosylated
using Peptide: N-Glycosidase F (PNGase F) under denatur-
ing conditions. Neuraminidase and PNGase F reactions were
carried out following the manufacturer’s directions (both
from New England Biolabs, Ipswich, MA). Band intensities
on Coomassie-stained gels or antibody- or lectin-decorated
immunoblots were quantiﬁed using Quantity One software
following image capture on a Gel Doc system (Bio-Rad
Laboratories, Mississauga, ON).
2.5. Open Column Chromatographic Puriﬁcation of Human
AGP. AGP was initially puriﬁed from human plasma using
the method of Herve et al. [29]. Except where indicated, all
buﬀers and solutions used in this study contained 0.02%
(w/vol) sodium azide as a bacteriostatic agent. Brieﬂy, 50mL
of plasma was dialyzed against 10mM sodium phosphate
pH 5.0 and then applied to a 200mL bed volume Aﬃ-Gel
Blue (agarose-coupled Cibacron Blue F3G-A dye) column
equilibrated with the same buﬀer. The ﬂow-through was
dialyzed against 10mM sodium phosphate pH 7.0, 100mM
NaCl, and applied to a 30mL bed volume Bio-Gel HT
hydroxyapatite column. After a 3-column volume wash, the
column was eluted with 20mM sodium phosphate, 100mM
NaCl. For brevity this procedure is referred to as Method 1.
2.6. Hot Phenol Puriﬁcation of AGP. In some experiments,
AGP was puriﬁed from plasma using the method of Chan
and Yu [23]. An equal volume of plasma was mixed with
25mL 10mM Tris-Cl pH 7.4 and combined with 50mL
of phenol saturated with sterile water. The phenol/plasmaJournal of Biomedicine and Biotechnology 3
mixture was heated to 70◦C for 20 minutes with stirring,
then placed on ice for 10 minutes and centrifuged for 10
minutes at 20,000×g. The supernatant was then subjected to
thesame Aﬃ-Gel Bluestepdescribedinthe previoussection.
For brevity, this procedure is designated Method 2.
2.7. Incorporation of ¨ AKTA Prime into Open Chromato-
graphic Puriﬁcation of AGP. Twenty-ﬁve mL of plasma was
chromatographed on Aﬃ-Gel Blue exactly as described in
Section 2.3,e x c e p tt h a ta1 0 0 m Lb e dv o l u m ew a sp a c k e d
into a column of 3.0cm internal diameter (I.D.). The ﬂow-
through was then dialyzed into 1mM sodium phosphate pH
7.0, 50mM NaCl, and loaded onto a CHT ceramic hydrox-
yapatite column (16mm I.D., 5mL bed volume) connected
toan ¨ AKTA-Primeautomatedliquidchromatographysystem
(GE Healthcare) at a ﬂow rate of 2mL/min. The column
was washed with load buﬀer, eluted stepwise with 50mM
NaCl containing either 5, 20, or 40mM sodium phosphate
pH 7.0, and purged with 500mM sodium phosphate pH 7.0,
500mM NaCl. Fractions from the middle steps were pooled
andconcentratedtocompletetheprocedure.Forbrevity,this
procedure is identiﬁed as Method 3 in this paper.
2.8. Sulphosalicylic Acid Preparation of AGP. AGP was ﬁrst
enriched by sulphosalicylic acid (SSA precipitation, as previ-
ously described [24, 25]). Twenty-ﬁve mL of human plasma
was precipitated using 8.3mL of ice-cold 12% (vol/vol) SSA.
The precipitate was pelleted by centrifugation at 4300× gf o r
15 minutes at 4◦C. The pH of the supernatant was adjusted
to 7.0 via the dropwise addition of5.0M NaOH and dialyzed
at 4◦C against 1mM sodium phosphate pH 7.0, 50mM
NaCl. It was loaded onto CHT ceramic hydroxyapatite using
the ¨ AKTA Prime system exactly as described in Section 2.5.
The eluate was dialyzed against 10mM sodium phosphate
pH 5.0 and applied to a prepacked 5.0mL HiTrap Blue
column on the ¨ AKTA Prime work station at 2mL/min.
The ﬂow-through was collected and concentrated by cycles
of ultraﬁltration and dilution using disposable centrifugal
concentration devices (Millipore, Billerica, MA) to change
thebuﬀerto20mMsodiumphosphatepH7.0,50mM NaCl,
as in Method 3. For brevity, this procedure is identiﬁed as
Method 4 in this paper.
2.9. Endotoxin Removal. Puriﬁed AGP preparations were
made 1% (v/v) in Triton X-114 and incubated, with rocking,
for 30 minutes at 4◦C. Following incubation in a 37◦C
water bath for 10 minutes, phase separation was achieved
by centrifugation at 20,000× g for 10 minutes. The upper
aqueousAGP-containing phase was drawn oﬀ.An yT ritonX-
114 that carried through was removed via adsorption to SM-
2 Bio-Beads, added to the aspirate at 0.3g/mL, and stirred
f o ra nh o u ra t4 ◦C. Endotoxin levels before and after this
procedurewere tested using thePyroGene assay kitfollowing
the manufacturer’s instructions.
2.10. Circular Dichroism. The circular dichroism spectrum
of puriﬁed AGP was determined using a J-600 spectropo-
larimeter (Jasco Analytical Instruments, Easton MD). AGP
was adjusted to 1.0mg/mL in 20mM sodium phosphate pH
7.0, 50mM NaCl and analyzed using a 0.1cm path length in
a cylindrical quartz cuvette. Spectra were acquired in 0.2nm
increments from 199 to 250nm, with a scanning speed of
50nm/min and were reported as the mean of 8 scans.
2.11. Animal Studies. Puriﬁed AGP preparations were radi-
olabeled using 125I-labeled sodium iodide by the Iodogen
method [30]. Rabbits weighing 2.3–3kg were injected via
the marginal ear vein with 4 × 106 dpm/kg of 125I-labeled
azide-free protein. Mice weighing 20–30g were injected
with 1.1–3.8 × 107 dpm/kg of 125I-labeled protein via
the tail vein. Blood sampling and determination of acid-
precipitable radioactivity in plasma was carried out as
previously reported by this laboratory for both species [31,
32]. Protein-bound radioactivity in the pellet was quantiﬁed
using a Packard Minaxi γ counter. Results were presented on
semilogarithmic clearance curves, either of the percentage of
the injected dose remaining in the animal over time or of
the percentage of acid-precipitable radioactivity remaining
in the plasma, normalized to take the ﬁrst, ﬁve-minute
postinjection plasma sample, as 100%. The former analysis
was employed in mice to probe recovery diﬀerences, and
the latter in rabbits. In the former instance, radioactivity
detected in the sampled plasma was extrapolated to whole-
body radioactivity assuming a murinebloodvolumeequalto
8% of body weight and a mean haematocrit of 40%. Animal
experiments employed procedures approved by the Animal
Research Ethics Board of the McMaster University Faculty of
Health Sciences.
2.12. Statistical Analysis. Data was analyzed using InStat
version 3.01 statistical analysis software (GraphPad, San
Diego, CA). A two-tailed Student’s t-test was employed
for parametric comparison and a Mann-Whitney test for
nonparametric comparison, taking P<. 05 to indicate
signiﬁcance. Data is reported as the mean ± the standard
deviation.
3.Results
A previous preliminary report from this laboratory suggested
an anti-inﬂammatory role of transfused puriﬁed human
AGP in a mouse model of early sepsis, using a dose of
0.13g/kg body weight [33]. Further investigation employing
such relatively high doses required us to ﬁnd a more eﬃcient
method of purifying AGP from human plasma.
Initially, we compared two published methods of
AGP puriﬁcation: one involving two chromatographic
steps, including a large (4mLresin/mL of plasma) column
(Method 1) [29] and a simpliﬁed procedure involving a hot
phenol extraction (Method 2) [23]. As shown in Figure 1(a),
in our hands the hot phenol method did not purify AGP to
homogeneity in a single step; instead both a 45kDa protein
immunoreactive with anti-AGP antibodies (data not shown)
and multiple polypeptides of lesser mobility were detected
on SDS-PAGE. In contrast, and as expected, in Method 1,
chromatography on a Cibracron Blue dye column yielded4 Journal of Biomedicine and Biotechnology
a mixture of AGP and primarily one other protein, and a
second hydroxyapatite chromatography step completed the
puriﬁcation to homogeneity. Adding an additional Cibacron
Blue dye chromatography step to the hot phenol Method 2
procedure rendered the two protocols equivalent in terms
of yielding electrophoretically pure AGP. Immunoblotting
of the two preparations gave an antibody decoration proﬁle
identical to the Coomassie-stained gel shown in Figure 1
(data not shown).
The in vivo behaviour of the two AGP preparations
following injection in mice was next examined following
radioiodination. As shown in Figures 1(b) and 1(c),A G P
puriﬁed by the hot phenol Method 2 left the murine
circulation more rapidly than that puriﬁed by the solely
chromatographic Method 1, as indicated by its lesser abun-
dance in sampled blood plasma at all time points that were
investigated, both in the initial equilibration (Figure 1(b))
andsubsequentterminal(Figure1(c))phasesofitsclearance.
For instance, the percentage of the injected dose found in
the blood at the ﬁrst time point (5 minutes post-injection)
was 67 ± 18% for chromatographically puriﬁed AGP versus
34 ± 17% (mean ± SD, n = 6, P = .0079) for hot
phenol-puriﬁedAGP.Twenty-fourhourslater,thisdiﬀerence
remained signiﬁcant, at 19 ± 6% versus 8.1 ± 2.7% (mean
± SD, n = 6, P = .0017). The area under the mean
observed clearance curve, a single measure capturing the
entire clearance proﬁle, was also reduced, from 730%-hours
for Method 1 AGP, to 324%-hours for Method 2 AGP.
Hypothesizing that the chemically harsh phenol treat-
ment could have resulted in loss of sialic acid residues, we
fullydesialylatedMethod1AGPbyneuraminidase treatment
(Figure 2(a), left). This procedure increased the mobility
of AGP, and, more importantly, eliminated its binding by
SNA lectin, which reacts with terminal sialic acid residues
linked to galactose (Figure 2(a),r i g h t ) .W en e x tc o m p a r e d
the binding of Method 1 and Method 2 AGP preparations,
at three diﬀerent dilutions, of either SNA lectin or anti-AGP
antibodies. As shown in Figure 2(b),t h er a t i oo fS N Al e c t i n
binding to anti-AGP binding varied at diﬀerent dilutions of
AGP but was always higher for Method 2 than Method 1.
These resultsindicated thatloss ofsialic acid residues did not
correlate with the more rapid in vivo clearance of Method 2
(hot phenol) AGP compared to Method 1 AGP.
It was nevertheless clear that some undesirable modi-
ﬁcation, conformational or otherwise, correlated with the
use of AGP Method 1, which involved a chemically harsh
hot phenol treatment. We sought to replace this puriﬁca-
tion step with a nonchromatographic procedure that also
rapidly enriched the preparation in AGP. As shown in
Figure 3(b), SSA precipitation enriched AGP from being a
minor component of plasma to being the most abundant
of 4 principal polypeptides in the SSA supernatant, similar
to the way in which ﬂowing through Cibacron Blue dye
columns enriched AGP in the alternative protocol. Note that
to facilitate comparison between the two methods, the two
procedures were adapted to use the AKTA Prime automated
liquid chromatography system, which necessitated using
forms of hydroxyapatite and immobilized Cibacron Blue dye
capable of withstanding elevated pressure. Using the form
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Figure 1: Comparison of AGP puriﬁed by solely chromatographic
Method 1 or hot phenol-incorporating Method 2. (a) shows
Coomassie-stained SDS reducing gels of equivalent (5μgt o t a l
protein/lane) samples of AGP preparations after initial (Cibacron
Bluedye columnﬂow-through,Aﬃ-BlueFT,orhotphenolaqueous
phase, Phenol sup.) or secondary hydroxyapatite chromatogra-
phy (HT), with the Method number given beneath, and the
position of molecular mass markers indicated between (in kDa)
the gel images. (b) shows the percentage of the injected dose
remaining in mice following injection of radioiodinated AGP
puriﬁed by either Method 1 or Method 2 (n = 6, mean ±
SD) versus time. (c) is identical to (b), except that the ﬁrst hour
post-injection is expanded to allow visualization of initial time
points.Journal of Biomedicine and Biotechnology 5
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Figure 2: Reaction of AGP with neuraminidase and reaction of
Method 1 versus Method 2 AGP with lectins and antibodies. AGP
puriﬁed by Method 2 (AGP; 2μg total protein/lane) was treated
with or without neuraminidase (neu-AGP) and examined on SDS
reducing gels or replica SNA blots (a). Molecular mass markers (in
kDa) are shown at left. (b) shows 0.25–1.0μg AGP from Methods 1
or 2 on blots probed either with Sambucus nigra agglutinin (SNA
Blot) or with Anti-AGP antibodies. The SNA: anti-AGP ratio of the
band intensities is shown beneath the lanes.
of hydroxyapatite optimized for high pressure (the so-
called “ceramic” hydroxyapatite) yielded slightly diﬀerent
results from ordinary hydroxyapatite, which necessitated
ﬁnal polishing on a high pressure form of immobilized
Cibacron Blue in Method 3, as opposed to the highly similar
Method 1. The only step diﬀering between the three-step
Methods 3 and 4 was therefore reduced to the initial passage
through a large immobilized Cibacron Blue dye column in
Method 3, versus SSA precipitation in Method 4. As shown
in Figure 3, this outcome was reproducible; three separate
preparations from each method yielded electrophoretically
indistinguishable preparations (Figures 3(a) and 3(b)),
which reacted bothwithanti-AGP antibodiesand SNAlectin
(Figure 3(c)).
The qualitative assessment of the eﬃcacy of Methods
3a n d4s h o w ni nF i g u r e3 was consistent with the more
quantitative data shown in Table 1,w h i c hu s e dE L I S A
t oq u a n t i f yA G Pl e v e l si nt h ep r o t e i nm i x t u r e sa te a c h
stage of puriﬁcation. The methods yielded similar levels
of enrichment, of 90- to 110-fold, and similar yields, of
324 to 372mg/L of plasma. Although Method 4 appeared
to give slightly lower yields than Method 3, this diﬀerence
may have arisen due to uncertainty in the ELISA or
total protein determinations, since both methods yielded
electrophoretically pure material, but diﬀered slightly in
speciﬁc activity (0.89mg AGP/mg total protein versus the
theoretically impossible 1.06mg AGP/mg total protein).
The clearance of AGP puriﬁed by Method 3 and Method
4 was compared in vivo following injection into rabbits.
Recoveries of the two forms of AGP did not diﬀer sig-
niﬁcantly (49.8 ± 5.4% versus 44.8 ± 1.7%, P = .262,
NS), allowing us to compare normalized plasma clearance
curves. As shown in Figure 4(a), these were essentially
superimposable. Where the mean curves diverged slightly
(at days 1, 4, and 7), the mean residual AGP plasma
concentration did not diﬀer signiﬁcantly. For instance, one
day post-injection, residual Method 3 AGP was 23.8 ±
1.9% versus 21.2 ± 1.6 for Method 4 AGP (mean ± SD,
P = .092, NS). Similarly, when circular dichroism, a
conformation-sensitive biophysical method [34], was used
to assess AGP puriﬁed by either of the methods, the spectra
were similarly indistinguishable (Figure 4(b)). Finally, AGP
puriﬁed by both methods yielded a single 20kDa species
when enzymatically deglycosylated with PNGase F, as was
also the case with commercially obtained AGP (Figure 4(c)).
No diﬀerence was observed between AGP preparations
in terms of the eﬃcacy of endotoxin removal. Preparations
contained signiﬁcant levels of endotoxin (130–230EU/mL)
prior to being subjected to depyrogenation via Triton X-
114 extraction, which reduced this load to 0.01–0.03EU/mL.
However, recovery varied widely, from 10.4 to 43.2% of
initially extracted AGP, and appeared to correlate not with
method of puriﬁcation, but with initial AGP concentration.
4.Discussion
Puriﬁcation of plasma proteins is often complicated by the
abundance of serum albumin, which contributes up to 50%
of the protein content of plasma, and the diﬃculty in com-
pletelyseparatingthisabundantcomponentfromtheprotein
of interest [35]. Although methods of plasma fractionation
have been established for many decades, frequently these
methods are not appropriate for small research laboratories
that lack access to industrial quantities of plasma. In this
context, albumin removal can seriously constrain the time
and complexity of plasma protein puriﬁcation.
Flow-through chromatography on Cibacron Blue dye
columns [35, 36]i sa ne ﬀective but limiting step in AGP
puriﬁcation, one that requires large columns (e.g., 4mL of
packed beads per mL of plasma) [29]. Initially, we sought
to optimize AGP puriﬁcation by substituting this step with
a hot phenol extraction previously reported to purify AGP
to homogeneity in a single step [23]. Although we did not
obtain full puriﬁcation in this single step, the enrichment
was suﬃcient to allow puriﬁcation to homogeneity with the
addition of a hydroxyapatite polishing step. However, AGP
puriﬁed by this procedure was more rapidly cleared from
the murine circulation than chromatographically puriﬁed
AGP not exposed to hot phenol. The clearance curves were
most easily explained by their being two populations of AGP
in the preparation: one, at least in part denatured and the
othernative in conformation[37].This interpretation would
predict that the ﬁrst population was rapidly removed from6 Journal of Biomedicine and Biotechnology
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Figure 3: Comparison of AGP puriﬁed by solely chromatographic Method 3 or sulphosalicylic acid-incorporating Method 4. (a) and
(b) show Coomassie-stained SDS reducing gels of equivalent (5μg total protein/lane) samples of AGP preparations at intermediate steps
of either Method of AGP puriﬁcation: Aﬃ-Blue FT, Cibacron Blue dye column ﬂow-through, CHT, ceramic hydroxyapatite peak; HT Aﬃ-
Blue,HiTrap Cibacron Bluedye columnﬂow-through;SSASup., supernatantfollowingsulphosalicylicacidprecipitation andneutralization.
(c) depicts nitrocellulose blots of replicated gels containing 1.0μg of puriﬁed human serum albumin (HSA) or of AGP puriﬁed by either
Method 3 (M3) or Method 4 (M4) and probed either with Anti-AGP antibodies (at left) or Sambucus nigra agglutinin (SNA lectin) at left.
The position of molecular mass markers and their mass in kDa is shown at left of each panel.
Table 1: Comparison of stepwise purity and yield of AGP puriﬁcation methods.
Total protein (mg) AGP (mg) AGP/total protein Fold enrichment versus starting material
Method 3
Plasma 1786 17.1 0.0096 1.0
Aﬃ-Gel Blue FT 86.6 17.8 0.21 21
CHT Eluate 16.3 9.1 0.56 58
HiTrap Blue FT 8.7 9.3 1.06 110
Method 4
Plasma 1786 17.7 0.0099 1.0
SSA Supernatant 43.3 13.3 0.31 31
CHT Eluate 20.8 7.8 0.38 38
HiTrap Blue FT 9.19 8.1 0.89 89
the circulation on initial passages prior to the ﬁrst blood
sampling, whereas the second was identical to chromato-
graphicallypuriﬁed AGP. The parallel nature ofthe clearance
curves supports this interpretation. Indeed, early investiga-
tors preconditioned radiolabeled protein by injection into a
ﬁrst animal, sampling of the blood, and its injection into a
second animal to ﬁlter out denatured radiolabeled material
[37]. Similarly, the presence of denatured protein has been
deduced in clearance studies by competition with agents
blocking reticuloendothelial uptake [38].
A reasonable hypothesis to account for the rapid clear-
ance ofthephenol-puriﬁed AGP was thatit had lost terminal
sialic acid residues and had therefore become a ligand for
the high-aﬃnity asialoglycoprotein, found predominantly
in the liver [39]. However, phenol-puriﬁed AGP reacted as
well, if not more avidly with Sambucus nigra agglutin in,
a lectin speciﬁc for glycans terminating in sialic acid linked
to galactose, than AGP puriﬁed under less harsh conditions.
While it remains possible that a few sialic acid residues were
lost per AGP molecule, a situation likely below the limits of
detection of the technique we employed, our results in this
regard eliminated the possibility of extensive desialylation.
Having established that the hot phenol procedure likely
distorted AGP conformation to an unacceptable extent, we
sought an alternative procedure that was rapid but nonde-
naturing. Like the hot phenol procedure, SSA treatment had
been reported to precipitate all other plasma proteins save
AGP, with the soluble, acidiﬁed AGP retaining the ability to
bind ligands such as Auramine O [24, 25]. Perhaps due to
improved electrophoretic methods, we detected additional
polypeptidesintheSSAsupernatant,whichwere nonetheless
removed in simpler, more rapid chromatographic steps than
the large Cibacron Blue dye column. That this procedure
(i.e., Method 4) was not only less limiting than the one
involving the large column, but also produced a similarly
native conformation of AGP was suggested not only byJournal of Biomedicine and Biotechnology 7
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Figure 4: In vivo clearance, circular dichroism spectra, and deglycosylation of AGP puriﬁed by Methods 3 or 4. (a) shows residual,
normalizedacid-precipitable radioactivity in rabbit plasma following injection of radioiodinated AGP puriﬁed as indicated by arrowed text.
(b) depicts circular dichroism spectra of AGP puriﬁed by Method 3 (upper) and Method 4 (lower); Δε represents the diﬀerence between the
absorption by AGP of left-handed and right-handed circularly polarized light at diﬀerent wavelengths. (c) shows samples of AGP puriﬁed
by either method, with (+) or without (−) reaction with PNGase F; reaction of commercial AGP (Sigma) is also shown. Molecular mass
markers are shown at left in kDa.
the identical in vivo clearance curves of radioiodinated
preparations of AGP prepared by the two methods, but
also by the identical circular dichroism spectra of the two
preparations. The latter method is exquisitely sensitive to
changes inproteinsecondarystructure [34].Notonlydidthe
two CD spectra match each other, they also closely resemble
previously published AGP spectra, in particular with respect
to the negative peak observed between 205 and 240nm, and
taking into account diﬀerences in CD methodology [40].
Methods 3 and 4 yielded similar quantities of AGP per
mL of plasma, but the SSA step in Method 4 eliminated the
large Cibacron Blue dye column without provoking denatu-
ration of the glycoprotein. Other procedures involving acid
conditions have been suggested to alter AGP conformation,
but these involved much longer exposure of the protein to
low pH (e.g., pH 3.85 for 16 hours) or exposure of AGP to
not only acid but also oxidizing agents (e.g., perchloric acid)
[21–26].
AGP in the circulation of most individuals is a combina-
tion of two isoforms produced by ORM1 and ORM2 genes,
which produce AGP proteins of identical polypeptide length
with similar glycosylation proﬁles, but which diﬀer at up to
23 amino acid positions within the chains [41]. Although
procedures have been described to separate these products,
they require the use of a large Cibacron Blue dye column
and buﬀers of pH less than 5.0 [42]. We did not address
isoform separation in this study, both because of its reported
use of a chromatographic step similar to the one we were
trying to remove from the puriﬁcation protocol,and because
isoform separation has not been carried out in studies of
AGP’s putative anti-inﬂammatory properties in vivo.
Our results suggest that incorporation of the SSA step
into an AGP puriﬁcation protocol simpliﬁed the procedure
while conserving the native conformation of the protein,
as indicated by biophysical and in vivo approaches. This
method should simplify the isolation of quantities of AGP
suﬃcient to explore its putative anti-inﬂammatory proper-
ties in small animal models, without concernsthat the native
conformation of the protein has been altered. It should be
noted that this study has limitations, especially with respect
to biophysical methods. Our use of circular dichroism to
compare the conformation of AGP preparations puriﬁed8 Journal of Biomedicine and Biotechnology
using Methods 3 or 4 at best yielded a rough estimate
that the conformations were similar. Others have performed
muchmorerigorousstudiesofAGPstructureusingvacuum-
ultraviolet CD in the presence of liposomes [40], mon-
itored organogold complex binding by AGP using CD
[43], and employed Raman and Fourier-transform infrared
spectroscopy [44–46] to probe AGP structure.
In spite of this limitation, and of the lackof an enzymatic
assay capable of reporting AGP conformation, our use of in
vivoclearancetodeduceanative conformationis anoveland
relevantwayofvalidatingtheSSA-incorporatingpuriﬁcation
protocol for future studies of AGP administration in animal
models.
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